Schizophrenia.
Morrison
Paul D
PD
Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK. paul.morrison@iop.kcl.ac.uk
Murray
Robin M
RM
D014150:Antipsychotic Agents / Q000627:therapeutic use; D001921:Brain / Q000033:anatomy & histology / Q000378:metabolism*; D002352:Carrier Proteins / Q000235:genetics; D002746:Chlorpromazine / Q000627:therapeutic use; D003024:Clozapine / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000627:therapeutic use; D000074765:Dysbindin; D049029:Dystrophin-Associated Proteins; D020022:Genetic Predisposition to Disease; D006801:Humans; D008279:Magnetic Resonance Imaging; D008959:Models, Neurological; D009419:Nerve Tissue Proteins / Q000235:genetics; D020890:Neuregulin-1 / Q000235:genetics; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology*; D012918:Social Alienation; D013569:Synapses / Q000378:metabolism*
D014150:Antipsychotic Agents; D002352:Carrier Proteins; C412476:DISC1 protein, human; C432416:DTNBP1 protein, human; D018492:Dopamine Antagonists; D000074765:Dysbindin; D049029:Dystrophin-Associated Proteins; D009419:Nerve Tissue Proteins; D020890:Neuregulin-1; D003024:Clozapine; D002746:Chlorpromazine; D004298:Dopamine